News headlines about AstraZeneca (LON:AZN) have trended neutral this week, according to InfoTrie Sentiment. The research group rates the sentiment of news coverage by reviewing more than 6,000 news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. AstraZeneca earned a media sentiment score of 0.11 on their scale. InfoTrie also assigned media coverage about the biopharmaceutical company an news buzz score of 10 out of 10, indicating that recent news coverage is extremely likely to have an impact on the stock’s share price in the near future.
These are some of the headlines that may have impacted AstraZeneca’s score:
- Neutral News Coverage Extremely Likely to Impact AstraZeneca (AZN) Stock Price (americanbankingnews.com)
- Intraday Healthcare Mover: AstraZeneca PLC (AZN) – Stock Digest (stockdigest.info)
- New Long-Term Data on CALQUENCE Presented at ASH 2018 (finance.yahoo.com)
- Global Meningioma Drug Market 2019 – AstraZeneca Plc, Eli Lilly and Co, Genentech Inc – Industry Strategy (industrystrategy24.com)
- 4 underrated FTSE 100 shares? J Sainsbury plc, HSBC Holdings plc, Aviva plc and AstraZeneca plc – Investomania (investomania.co.uk)
AZN has been the subject of several research reports. Barclays restated an “overweight” rating on shares of AstraZeneca in a research note on Tuesday, October 9th. JPMorgan Chase & Co. restated an “overweight” rating and issued a GBX 6,500 ($84.93) target price on shares of AstraZeneca in a research note on Friday, October 19th. Shore Capital restated a “hold” rating on shares of AstraZeneca in a research note on Tuesday, October 16th. Jefferies Financial Group restated a “hold” rating and issued a GBX 5,800 ($75.79) target price on shares of AstraZeneca in a research note on Friday, October 12th. Finally, Credit Suisse Group set a GBX 6,350 ($82.97) target price on AstraZeneca and gave the company a “buy” rating in a research note on Thursday, August 30th. Two research analysts have rated the stock with a sell rating, eight have assigned a hold rating and eleven have assigned a buy rating to the stock. The stock has a consensus rating of “Hold” and an average price target of GBX 5,927.44 ($77.45).
AstraZeneca Company Profile
AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
Featured Article: Yield Curve
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.